Vaxcyte, Inc. (PCVX)

Vaxcyte Statistics

Total Valuation

Vaxcyte has a market cap or net worth of $8.24 billion. The enterprise value is $6.62 billion.

Market Cap	8.24B
Enterprise Value	6.62B

Important Dates

The last earnings date was Wednesday, May 6, 2026, after market close.

Earnings Date	May 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Vaxcyte has 144.39 million shares outstanding. The number of shares has increased by 7.07% in one year.

Current Share Class	144.39M
Shares Outstanding	144.39M
Shares Change (YoY)	+7.07%
Shares Change (QoQ)	+2.25%
Owned by Insiders (%)	0.67%
Owned by Institutions (%)	96.02%
Float	132.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.75
P/TBV Ratio	2.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.49, with a Debt / Equity ratio of 0.04.

Current Ratio	7.49
Quick Ratio	7.18
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -30.55% and return on invested capital (ROIC) is -21.27%.

Return on Equity (ROE)	-30.55%
Return on Assets (ROA)	-20.23%
Return on Invested Capital (ROIC)	-21.27%
Return on Capital Employed (ROCE)	-35.05%
Weighted Average Cost of Capital (WACC)	11.24%
Revenue Per Employee	n/a
Profits Per Employee	-$1.87M
Employee Count	507
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +66.57% in the last 52 weeks. The beta is 1.30, so Vaxcyte's price volatility has been higher than the market average.

Beta (5Y)	1.30
52-Week Price Change	+66.57%
50-Day Moving Average	58.52
200-Day Moving Average	46.49
Relative Strength Index (RSI)	44.71
Average Volume (20 Days)	1,143,833

Short Selling Information

The latest short interest is 14.36 million, so 9.94% of the outstanding shares have been sold short.

Short Interest	14.36M
Short Previous Month	13.69M
Short % of Shares Out	9.94%
Short % of Float	10.82%
Short Ratio (days to cover)	10.71

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-1.09B
Pretax Income	-946.53M
Net Income	-946.53M
EBITDA	-1.07B
EBIT	-1.09B
Earnings Per Share (EPS)	-$6.91

Balance Sheet

The company has $1.74 billion in cash and $116.30 million in debt, with a net cash position of $1.62 billion or $11.23 per share.

Cash & Cash Equivalents	1.74B
Total Debt	116.30M
Net Cash	1.62B
Net Cash Per Share	$11.23
Equity (Book Value)	3.00B
Book Value Per Share	20.76
Working Capital	1.57B

Cash Flow

In the last 12 months, operating cash flow was -$769.93 million and capital expenditures -$45.02 million, giving a free cash flow of -$814.94 million.

Operating Cash Flow	-769.93M
Capital Expenditures	-45.02M
Depreciation & Amortization	16.39M
Net Borrowing	n/a
Free Cash Flow	-814.94M
FCF Per Share	-$5.64

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vaxcyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.07%
Shareholder Yield	-7.07%
Earnings Yield	-11.48%
FCF Yield	-9.88%

Analyst Forecast

The average price target for Vaxcyte is $88.25, which is 54.55% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$88.25
Price Target Difference	54.55%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1